Last reviewed · How we verify

NCT06760988

Efficacy of CL22205 to Improve Menstrual Discomfort and Quality of Life

Not yet recruiting NA Last updated 7 March 2025
What this trial tests

NA trial testing CL22205 in Menstrual Discomfort in 80 participants. Not yet recruiting.

Timeline
24 February 2025
Primary endpoint
5 October 2025
10 January 2026

Quick facts

Lead sponsorEetho Brands, Inc
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposehealth services research
Enrollment80
Start date24 February 2025
Primary completion5 October 2025
Estimated completion10 January 2026

Drugs / interventions tested

Conditions studied

Sponsor

Eetho Brands, Inc

Who can join

Adults 25 to 35, female only, with Menstrual Discomfort. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy of CL22205 to improve menstrual discomfort and quality of life in oligomenorrheic female subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of CL22205

Trials testing the same drug.

Other recruiting trials for Menstrual Discomfort

Currently open trials in the same condition.

Other Eetho Brands, Inc trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06760988.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing